乐动体育


Trial Watch

Leading Results Leading Results

Challenged Results Challenged Results

Merck’s Keytruda Shows Mixed Results in Phase 3 Lung Cancer Trial

Merck’s Keytruda Shows Mixed Results in Phase 3 Lung Cancer Trial

乐动体育Merck reported mixed results from the phase 3 KEYNOTE-604 trial investigating Keytruda, Merck’s anti-PD-1 therapy, in combination with chemotherapy in the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC). The trial met one of its...

subscribe

Pin It on Pinterest